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Hepatocellular carcinoma (HCC) ranks third in overall global cancer-related mortality. Symptomatic presentation often means
advanced disease where potentially curative treatment options become very limited. Numerous international guidelines propose
the routine monitoring of those with the highest risk factors for the condition in order to diagnose potential tumourigenesis early.
To aid this, the fields of metabonomic- and proteomic-based biomarker discovery have applied advanced tools to identify early
changes in protein and metabolite expression in HCC patients vs controls. With robust validation, it is anticipated that from these
candidates will rise a high-performance non-invasive test able to diagnose early HCC and related conditions. This review gathers
the numerous markers proposed by studies using mass spectrometry and proton nuclear magnetic resonance spectroscopy and
evaluates areas of consistency as well as discordance.
Hepatocellular carcinoma (HCC) ranks third in overall global
cancer-related mortality (Ferlay et al, 2010) accounting for 85–
90% of all tumours emerging from the liver in high-incidence
areas and between 70 and 75% of cases in lower incidence
regions. In a 2008 survey, overseen by the World Health
Organisation (WHO), it was reported that there were B748 000
new cases of liver cancer diagnosed worldwide, in that year alone,
with an estimated 695 000 reported deaths in the same period
(Ferlay et al, 2010). These figures reflect the high mortality rate of
this disease owing to multiple contributing factors; most
important of which include the absence of monitoring in high-
risk populations, insufficient diagnostic resources, and very
limited treatment options, many of which require early tumour
identification for any potential of curative intervention. As a
consequence, the HCC biomarker discovery field is rapidly
expanding with new and ongoing research continuing to propose
a fast growing list of biomarker candidates. Many of these
candidate biomarkers await further validation before being used
in conjunction with, or in place of ultrasound scanning as the
primary non-invasive test for HCC determination.
The main risk and causative factors for HCC are well described
in the literature with a distinct geographical separation observed
between established infectious agents such as the hepatitis B and C
viruses (HBV and HCV) vs an increasing number of lifestyle-
related risk factors such as chronic alcohol abuse (Morgan et al,
2004) non-alcoholic steatohepatitis, diabetes and obesity
(Regimbeau et al, 2004; El-Serag and Rudolph, 2007). The focus
of this review is to summarise and explore the new potential
candidate biomarkers arising from the surge of proteomic and
metabolic profiling studies infiltrating the literature. The advance
of these markers through the implementation of systems biology
approaches will bring to the forefront robust candidates for
enhanced diagnostics and therapies for chronic liver diseases
(CLDs; Bertino et al, 2014; Malaguarnera et al, 2014). The key
selection criteria for an ideal biomarker for any disease are for the:
 Target molecule to be measurable in a non-invasive sample
source such as blood or urine.
 Marker to have excellent diagnostic and/or prognostic abilities
for condition of interest (i.e., high sensitivity and specificity).
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 Marker should be amenable to measurement techniques that are
reliable, robust, and reproducible and, for use in field analysis
should ideally take a simple kit-based format not requiring
additional equipment for interpretation.
 Assay should be cheap and thus accessible to all the populations
requiring it.
 The biomarker should be validated across a broad range of
populations.
Currently the most widely used biomarker for HCC, particularly
in the developing world where disease burden is greatest is alpha-
fetoprotein (AFP). Alpha-fetoprotein ticks several of the boxes in
relation to the points mentioned above but fails dramatically in its
diagnostic performance and ability, thus significantly reducing its
reliability in clinical settings.
The role of AFP in diagnosing HCC and monitoring those at
high risk of its development is heavily constrained, with revised
guidelines reflecting its significant limitations in this regard. A
publication by the American Association for the Study of Liver
Diseases (AASLD) summarises that AFP ‘lacks adequate sensitivity
and specificity for effective surveillance and for diagnosis’ of HCC
(Bruix and Sherman, 2011). Similarly, the European Association
for the Study of the Liver (EASL) does not recommend AFP within
the panel of tests for HCC diagnosis (European Association for the
Study of the Liver and European Organisation for Research and
Treatment of Cancer, 2012). Not much has been reported on the
independent diagnostic ability of AFP, but it is approximated at
0.70, with at least one publication showing area under the curve
(AUC) values as low as o0.60 when used at a cut-off of
100 ngml 1 (Giannini et al, 2012). To circumvent this problem,
advanced radiological methods are increasingly being relied on as
the best non-invasive tools for accurate diagnosis and monitoring
of CLD patients. However, as CLDs and their sequelae of
conditions inflict their biggest burden in the developing world,
this shift has meant that many of the patients mostly in need of
monitoring and diagnosis are left to rely on the poor performance
of AFP. The AASLD and EASL both recommend routine
surveillance of patients with chronic hepatitis infections and
fibrosis, to detect HCC at the early disease stage, when curative
treatment options such as tumour resection (Bruix and Sherman,
2011), ablation (Livraghi et al, 2008), transarterial chemoembolisa-
tion (Llovet and Bruix, 2003), and liver transplant, recommended
for patients with localised tumours on a background of advanced
cirrhosis are still prospective. To make this a reality, there is an
urgent need for the identification and conversion into clinical use
of affordable, non-invasive, and high-performance diagnostic tools
deployable in both the developing and developed worlds.
With the availability of novel state-of-the-art technologies and
approaches, medical researchers have in recent years used the tools
of mass spectrometry (MS) and proton nuclear magnetic resonance
(1H NMR) spectroscopy to delve deeper into the human proteome
and metabolome from accessible body fluids in order to identify
high-performance screening and diagnostic markers capable of
detecting and or predicting HCC development. However, there are
currently no clinically approved alternatives to AFP that could
form robust, non-invasive routine tests available to confidently
detect HCC or its main precursor condition of liver cirrhosis (LC)
at their early stages. This review aims to summarise and assess
literature reports of the application of 1H NMR spectroscopy and
MS methods to identify and validate the differential expression of
proteins, and metabolites potentially exploitable as biomarkers of
HCC. Some degree of focus will be given to markers of earlier
stages of CLD such as liver fibrosis and LC where they have been
reported. However, due to the high degree of variability in research
approaches used to validate the expression trends of putative
biomarkers and the small sample sizes generally utilised in
profiling, a true meta-analysis of all published work is as yet not
possible. Part of the selection criteria for inclusion of papers in this
review was that all initial discovery of proposed markers was to be
conducted using spectroscopic methodologies, it may thus be
striking that some of the more widely proposed markers associated
with HCC and CLDs are absent. These have mainly been proposed
in experiments utilising more classical protein and metabolite
identification and measurement methods, and thus do not form
the focus of this work. Many of these classical markers have been
widely discussed and reviewed in the context of liver diseases
(Bertino et al, 2012; Masuzaki et al, 2012). Several worthy of
mention include des-carboxy prothrombin, squamous cell carci-
noma antigen–immunoglobulin M complexes, and chromogranin
A, which have been proposed and/or compared with AFP in key
publications (Bertino et al, 2010, 2011; Biondi et al, 2012). As the
list of candidate markers being identified and proposed byspectro-
scopic methods increases, it is important that reports are
comprehensively amalgamated in order to allow researchers to
focus more on validating their robustness and expression patterns
using independent methods and platforms. This review is an
attempt to accelerate this agenda and to ascertain which panel of
metabolites and proteins would offer a parsimonious and robust
solution for an effective diagnosis.
MATERIALS AND METHODS
This review focuses on biomarkers proposed from sources searched
in the databases PubMed and Google Scholar. The exact search
procedure is outlined in Figure 1. For the identification of
proteomic papers, the PubMed database was searched with the
term ‘(((Hepatocellular Carcinoma) AND Biomarker) AND
Proteomics)’. For the metabonomics part, a similar PubMed
search was conducted (but with the word ‘metabonomics’ instead
of ‘proteomics’). All returned publications shortlisted for
Proteomics
Hepatocellular carcinoma
biomarker
29 Hits
Search and identify hits in references
16 Hits
29 Hits 22 Hits
5 Hits
17l
Publications
26
Publications
464
Publications
Hepatocellular carcinoma
biomarker
Metabonomics
Figure 1. The search terms ‘Proteomics’ or ‘Metabonomics’ and
‘Hepatocellular Carcinoma’ and ‘Biomarker’ were entered into the
search engine PubMed (http://www.ncbi.nlm.nih.gov/pubmed). For the
identification of metabonomic publications, an additional Google
Scholar search was conducted for the time range 2003–2013 (http://
scholar.google.co.uk/).
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adherence to the inclusion/exclusion criteria stated below were
considered for analyses. Since only 10 metabonomic publications
were identified on PubMed, an additional Google Scholar search
was conducted, which identified a further eight publications.
Additional publications were identified by screening all references
associated with these primary papers.
The criteria for inclusion in this review were:
 HCC biomarker studies using plasma, serum, or (for metabo-
nomic papers) urine.
 HCCs linked to established viral and dietary risk factors with no
reports of metastases.
 Initial discovery conducted on a MS or 1H NMR spectroscopy-
based platform.
Exclusion criteria were non-English literature reports, studies on
tissues, cell lines, or animals. Studies including subjects who
underwent surgery or transplant were also excluded in order to
avoid cases of recurrent HCC following treatment or intervention –
these recurrences may have unique developmental profiles that
could influence scope of targets identified. Once this initial filtering
was applied, a secondary criterion including biomarker candidates
with multiple reports, that is, the biomarker should have been
reported by at least two independent methods or research groups,
was applied.
HCC markers proposed by metabonomic studies. The liver is
the metabolic hub of humans as most compounds absorbed by the
intestine pass through it at least once. Owing to this, it is able to
regulate the expression levels of numerous metabolites, which
makes metabolomic analyses approaches particularly relevant for
the investigation of liver diseases, such as LC and HCC. In recent
years, a lot of effort has been put into metabonomic research on
CLDs mainly using urine, blood, or hepatic tissue sections. A
number of differential metabolites have been reported by the few
studies on HCC tumour tissues, suggesting that there are major
metabolic changes taking place during disease development and
progression. A common finding of these studies is a glycolytic
HCC phenotype (Yang et al, 2007b; Beyog˘lu et al, 2013), indicating
that the Warburg effect may take place in liver cancer. Although
this and other findings give important insight into HCC tumour
biology from a clinical perspective, a more important question is
whether there exist specific metabolites detectable in biofluids, such
as blood or urine, which can serve as biomarkers for the diagnosis
of early HCC.
Up to the submission of this review, 22 metabonomic studies
matched the inclusion criteria described above and investigated the
blood and/or urine metabolome in the context of HCC (Table 1).
Most of these studies are MS based and investigate HCC in the
context of HBV or HCV (Table 2), which reflects the global trend
of primary HCC risk factors (Boyle and Levin, 2008). In contrast,
the patient cohorts’ ethnicities in these studies did not reflect the
geographical distribution of HCC incidence. Although the majority
of studies were performed in China, where HCC is a major health
issue, only a single study investigated the metabolome of HCC in a
sub-Saharan African cohort (Table 2), where HCC is an equally
important health burden (Ferlay et al, 2010).
Most studies inferred differential expression of metabolites by
comparing either serum or urine profiles of HCC patients with
control groups, mainly made up of healthy volunteers or cirrhotics.
This was accomplished with univariate and/or multivariate
statistical methods. Multivariate methods used in these publica-
tions not only include partial least squares discriminant analysis
(PLS-DA), but also support vector machine and random forest
approaches. On average 18 biomarker candidates were identified
per study, with only 32% of these using established diagnostic
models for comprehensive assessment of diagnostic performance.
This low assessment rate makes a meta-analysis impossible at this
stage.
The following section is structured according to compound
classes to provide an overview of the metabolites that were
reported in more than one study. In addition, the diagnostic
models that have been reported to perform extremely well in
diagnosing HCC will be mentioned at the end of this section.
Bile acids. Bile acids constitute one of the most frequently
reported compound classes suggested as discriminating between
HCC patients and a control group, be it healthy or CLD. An
increase in conjugated bile acids has long been recognised in
patients with hepatobiliary diseases in general, such as viral
hepatitis, cirrhosis, HCC, and cholangiocarcinoma (Neale et al,
1971). Many metabonomic publications reviewed here confirm an
increase in particular conjugated serum bile acids in HCC patients
when compared to healthy individuals (Table 3).
Interestingly, higher bile acid serum levels (glycochenodeoxy-
cholic acid, glycocholic acid, CA, and deoxycholic acid (DCA))
have been found in HCC patients with cirrhosis, than without
(Chen et al, 2011b), which may indicate that the bile acid
concentration is primarily associated with cirrhosis or overall
hepatic performance. Evidence for this is given by Chen et al, 2012,
who found serum bile acids increased in patients with hepatic
decompensation, when compared to compensated patients. A
closer look at the HCC cohorts’ characteristics of the matched
studies reveals that only a few assessed and included the extent of
liver disease in the background of HCC or the hepatic compensa-
tion/decompensation status in their analyses (Table 2). This may
have significantly biased the results. Other confounding factors
that have not been controlled for many studies include (1) the
prandial state of the patients (elevated serum levels of certain bile
acids have been reported previously in patients after food intake
(LaRusso et al, 1978; Ponz De Leon et al, 1978)) and (2) the size of
the tumour mass. Large tumour masses may compromise the
ability of non-tumourous liver tissue to produce bile acids, thereby
lowering the serum bile acid levels. Although some studies report
the fraction of HCC patients in different tumour stages, the
majority of studies did not include that information in their data
analyses.
Altogether, the level of serum bile acids reported here seems to
be associated primarily with cirrhosis and not HCC and we do not
recommend this compound group as biomarkers for early HCC
without further directed analysis of the bile acids across different
stages of cirrhosis. From a mechanistically viewpoint, bile acids
may play a role in the development of HCC, for example, by the
production reactive oxygen species, thereby producing oxidative
stress and DNA damage (Baptissart et al, 2013). Some of the
bile acids have also been described as versatile signalling
molecules (Thomas et al, 2008, 2009; Gadaleta et al, 2011), for
instance, lithocholic acid and DCA are both involved in the
promotion of energy expenditure and participation in glucidic
metabolism by acting on the G-protein-coupled receptor TRG5
(Baptissart et al, 2013).
Table 1. Number of metabonomic publications broken down
to platform and specimen type
Biofluid 1H NMR MS Total
Urine 2 3 (1a) 5
Serum/plasma 3 13 (4a) 16
Both — 1 1
Total 5 17 22
Abbreviations: 1H NMR¼proton nuclear magnetic resonance; MS¼mass spectrometry.
aNumber of studies that included a validation cohort.
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Table 2. Summary of metabonomic studies that were reviewed
HCC group
Reference Biofluid Platform
Cohort
sizes
Validation
cohort Aetiology
Sex
(m : f)
Background
CLD Ethnicity Staging
Baniasadi et al, 2013 Serum HPLC–MS/MS (MRM) HCC: 30
CIR: 22
No HCV 3.3 : 1 Yes Mainly Caucasian No
Chen et al, 2011a Serum UPLC–MS/MS HCC: 41
HCON: 38
No HBV 2 : 1 No information Chinese No
Chen et al, 2013b Serum UFLC–IT–TOF/MS HCC: 30
CIR: 30
CHB: 30
HCON: 30
No HBV No
information
No information Chinese No
Chen et al, 2013a Serum UHPLC–TQ–MS
(MRM)
HCC: 29
HCON: 30
No No
information
No
information
No information No information No
Chen et al, 2011b Serum, urine GC–TOF–MS,
UPLC–qTOF–MS
HCC: 82
Benign
LD: 24
HCON: 71
Yes Mainly HBV 2 : 1 Majority yes Chinese TMN
Chen et al, 2009 Urine RPLC–qTOF–MS,
HILIC–qTOF–MS
HCC: 21
HCON: 24
Yes No
information
Partially No information Chinese No
Gao et al, 2009 Serum 1H NMR HCC: 39
CIR: 36
HCON: 63
No HCC: HCV
CIR: No
information
No
information
No information Chinese No
Huang et al, 2013 Serum UHPLC–MS
CE–MS
HCC: 139
CIR: 78
CHB: 81
Yes HCC: Mainly
HBV
CIR: HBV
5.3 : 1 No information No information No
Nahon et al, 2012a Serum 1H NMR HCC: 61
CIR: 93
Yes Alcohol 1 : 0 Yes Caucasian or
residence in France
Small HCC
Large HCC
Patterson et al, 2011 Plasma UPLC–qTOF–MS
UPLC–TQ–MS (MRM)
GC–MS
HCC: 20
CIR: 7
AML: 22
HCON: 6
No HCC: Mixed
CIR: No
information
5.6 : 1 Majority yes No information Barcelona
criterion
Ressom et al, 2012 Serum UPLC–qTOF–MS,
UPLC–MS (SRM)
HCC: 78
CIR: 184
No HCC: Mainly
HCV
CIR: Mixed
5.5 : 1 Yes Mainly Caucasian Yes (system not
specified)
Shariff et al, 2011 Urine 1H NMR HCC: 16
CIR: 14
HCON: 17
No Mainly HCV 15 : 1 Majority yes Egyptian Okuda
Shariff et al, 2010 Urine 1H NMR HCC: 18
CIR: 10
HCON: 14
No HCC: Mainly
HBV
CIR: HBV
2 : 1 No information Nigerian Okuda
Wang et al, 2012 Serum UPLC–MS HCC: 23
CIR: 28
HCON: 70
Yes HBV 12 : 1 Partially Chinese AJCC
Wei et al, 2012 Serum 1H NMR HCC: 40
CHC: 22
No HCV 3.3 : 1 No information Mainly Caucasian No
Wu et al, 2009 Urine GC–MS HCC: 20
HCON: 20
No No
information
1 : 0 No information Chinese No
Xiao et al, 2012 Serum UPLC–qTOF–MS
UPLC–MS/MS (SRM)
HCC: 40
CIR: 49
No HCC: HCV
CIR: Mainly
HCV
3.4 : 1 No information Egyptian TMN
Xue et al, 2008 Serum GC–MS HCC: 20
HCON: 20
No No
information
1 : 0 No information Chinese No
Yin et al, 2009 Serum RPLP–qTOF–MS,
HILIC–qTOF–MS
HCC: 24
CIR: 25
HCON: 25
No HCC: No
information
CIR: HBV
No
information
Partially Chinese No
Zhang et al, 2013 Urine UPLC–qTOF–HDMS HCC: 25
HCON: 12
No No
information
1 : 1 No information Chinese No
Zhou et al, 2012a Serum UPLC–qTOF–MS
(MRM)
HCC: 69
CIR: 28
HCON: 31
No HBV and
HCV
4.3 : 1 No information Chinese No
Zhou et al, 2012b Serum RPLC–qTOF–MS HCC: 30
CIR: 30
CHB: 30
HCON: 30
No No
information
2.3 : 1 Yes Chinese No
Abbreviations: AJCC¼American Joint Committee on Cancer; AML¼ acute myeloid leukaemia; CE¼ capillary electrophoresis; CHB¼ chronic hepatitis B; CHC¼Carcinome HepatoCellulaire;
CIR¼ cirrhosis cohort; CLD¼ chronic liver disease; GC¼gas chromatography; HBV¼ hepatitis B virus; HCC¼ hepatocellular carcinoma; HCON¼ healthy control cohort; HCV¼ hepatitis C
virus; HDMS¼high-definition mass spectrometry; HILIC¼ hydrophobic interaction chromatography; IT¼ ion trap; MRM¼multiple reaction monitoring; MS¼mass spectrometry; NMR¼
nuclear magnetic resonance; qTOF¼quadrupole time of flight; RPLC¼ reversed phase liquid chromatography; SRM¼ single reaction monitoring; TOF¼ time of flight; TQ¼ triple quadrupole;
UFLC¼ ultra-fast liquid chromatography; UHPLC¼ultra-high-performance liquid chromatography; UPLC¼ultra-performance liquid chromatography.
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Conflicting urinary concentrations of free glycine and taurine,
two bile acid conjugates, have also been reported. These equivocal
reports may also be explained by the recruitment of heterogeneous
study cohorts (which differ in the degree of background liver
disease or tumour masses). Since, both of the amino acids, glycine
and taurine exhibit a wide range of metabolic activity, it is likely
that their serum and urine concentrations in HCC patients reflect
multiple metabolic processes, which further complicates the
interpretation of these results. Less frequently reported bile
compounds include various other bile acid species.
Lysophosphatidylcholines. When compared to a healthy control
group, nine lysophosphatidylcholines (LPCs) have been reported to
be significantly decreased in the sera of HCC patients in multiple
publications (Table 4). The most frequently reported species
include LPC C16 : 0, LPC C18 : 0, and LPC C18 : 2. Two of these
(LPC 16 : 0 and LPC 18 : 0) have also been reported to be
differentially expressed in the sera of HCC patients when
compared with cirrhotic patients, with increased serum levels of
LPC C18 : 0 and inconclusive findings for LPC C16 : 0. The
depletion of LPC C16 : 0 in HCC tumours has recently been
described by two independent tissue metabonomic studies
(Beyog˘lu et al, 2013; Huang et al, 2013). Transcriptomic analyses
confirmed the overexpression of lysophosphatidylcholine acyl-
transferase 1 (LPCAT1), which converts LPC C16 : 0 to phospha-
tidylcholine 18 : 1 (Morita et al, 2013). This upregulation of
LPCAT1 could account for the depletion of LPC C16 : 0. However,
some LPC species, including 16 : 0, LPC 18 : 0, LPC 20 : 4, and LPC
20 : 5 have also been described as differentially expressed between
hepatic decompensated and compensated patients (Chen et al,
2012). As mentioned before, many studies did not control for the
background liver disease, that is, hepatic performance, which could
have biased the described findings.
LPCs, together with arachidonic acid, may play important roles
in the progression of HCC, as they have been described as
important players in endothelial cell migration, that is, vascular-
isation processes (Linkous et al, 2010). This finding matches with
the observation that hypervascularisation is a frequent feature of
HCC. A positive relationship has been described between LPC
concentrations and both body weight and inflammatory processes
in malignant diseases (Taylor et al, 2007). The detection of urinary
LPCs in the context of HCC has not been reported.
Table 3. Bile acid compounds discriminatory between HCC and comparison group
HCC: Healthy HCC: Cirrhosis
Compound HMDB ID Association Serum Urine Serum Urine
GCA 00138 Bile acid m (Yin et al, 2009; Chen et al, 2011b;
Zhou et al, 2012a, b)
m (Chen et al, 2011b; Zhang et al,
2013)
k (Ressom et al, 2012;
Xiao et al, 2012)
GCDCA 00637 Bile acid m (Yin et al, 2009; Chen et al, 2011b;
Wang et al, 2012; Zhou et al, 2012b)w
k (Wang et al, 2012;
Xiao et al, 2012)
GDCA 00631 Bile acid m (Patterson et al, 2011; Zhou et al,
2012a)
k (Ressom et al, 2012;
Xiao et al, 2012)
TCA 00036 Bile acid m (Yin et al, 2009; Chen et al, 2011b)w
TCDCA 00951 Bile acid k (Ressom et al, 2012;
Xiao et al, 2012)
Glycine 00123 Bile acid conjugate k (Shariff et al, 2011)
m (Wu et al, 2009)
Taurine 00251 Bile acid conjugate k (Yin et al, 2009)
m (Chen et al, 2011b)
Abbreviations: GCA¼glycocholic acid; GCDCA¼glycochenodeoxycholic acid; GDCA¼glycodeoxycholic acid; HCC¼ hepatocellular carcinoma; HCV¼ hepatitis C virus; HMDB¼The Human
Metabolome Database; TCA¼ taurocholic acid; TCDCA¼ taurochenodeoxycholic acid. k indicates decrease in HCC; m indicates increase in HCC; w indicates control group of the study (Yin
et al, 2009) comprised chronic HCV carriers.
Table 4. LPCs reported to be discriminatory between HCC and comparison groups
HCC: Healthy HCC: Cirrhosis
Compound HMDB ID Association Serum Urine Serum Urine
LPC C14 : 0 10379 Phospholipid catabolism k (Patterson et al, 2011; Zhou et al, 2012b; Chen et al,
2013a)
LPC C16 : 0 10382 Phospholipid catabolism k (Patterson et al, 2011; Wang et al, 2012; Zhou et al,
2012a; Chen et al, 2013a, b)
k (Patterson et al, 2011;
Zhou et al, 2012a)
m (Ressom et al, 2012;
Wang et al, 2012)
LPC C18 : 0 10384 Phospholipid catabolism k (Yin et al, 2009; Patterson et al, 2011; Wang et al, 2012;
Zhou et al, 2012a; )
m (Ressom et al, 2012;
Wang et al, 2012)
LPC C18 : 1 02815/10385/10408 Phospholipid catabolism k (Patterson et al, 2011; Zhou et al, 2012a; Chen et al,
2013a)
LPC C18 : 2 10386 Phospholipid catabolism k (Yin et al, 2009; Zhou et al, 2012a; Baniasadi et al, 2013;
Chen et al, 2013a, b)
LPC C18 : 3 10386 Phospholipid catabolism k (Yin et al, 2009; Patterson et al, 2011)
LPC C20 : 3 10393/10394 Phospholipid catabolism k (Patterson et al, 2011; Zhou et al, 2012b)
LPC C20 : 4 10395/10396 Phospholipid catabolism k (Patterson et al, 2011; Zhou et al, 2012a)
LPC C20 : 5 10397 Phospholipid catabolism k (Patterson et al, 2011; Zhou et al, 2012b)
Abbreviations: HCC¼ hepatocellular carcinoma; HMDB¼The Human Metabolome Database; LPCs¼ lysophosphatidylcholines. k indicates decrease in HCC; m indicates increase in HCC.
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Free fatty acids. Although numerous free fatty acid (FFA) species
have been described as being discriminatory in serum between
HCC patients and a control group, there was no common trend in
serum FFA levels observable with some studies reporting increased
levels and others reporting a decrease in FFA concentrations
(Table 5). FFA species reported frequently include FFA C16 : 0,
FFA C18 : 0, FFA C20 : 4, and FFA C24 : 1. The conflicting reports
on the serum concentrations may be a result of heterogenic patient
groups, in terms of different diets, gender, comorbidities (such as
cardiovascular diseases), and of course the extent of liver damage,
that is the hepatic compensation/decompensation status. As was
the case for bile acids and LPCs, FFA levels seem to be also
influenced by background liver disease (Chen et al, 2012). The
association of FFA 16 : 0 and FFA 18 : 0 with hepatitis B and
cirrhosis has been described by Chen et al, 2011b, who investigated
HCC patients with and without LC and hepatitis separately. In
contrast, increased concentrations of FFA C16 : 0 and FFA C18 : 0
have been confirmed by a tissue metabonomic study on HCC
(Huang et al, 2013), indicating that there may be quantitative
differences between serum FFA concentrations of HCC and
cirrhosis patients.
Other serum lipid compounds found to be discriminative
between HCC and healthy controls are FFA C24 : 1 and oleamide.
Although FFA 24 : 1 has not been found to discriminate between
cirrhosis and HCC patients, oleamide has. Oleamide, the amide of
FFA C18 : 1 (oleic acid), exhibits a variety of neuropharmacological
effects, including increased food intake (Martı´nez-Gonza´lez et al,
2004) and relaxation of blood vessels (Hoi and Hiley, 2006). Since
Oleamide has not been associated with CLDs, nor previously been
reported in cancer literature, it may represent a specific marker for
HCC. However, further validation studies are required.
Carnitine and related acylesters. A compound class closely
associated to fatty acids and their catabolism, is carnitine and its
acylesters. Carnitine is mainly derived from dietary sources and its
main function is to transport activated long-chain fatty acids from
the cytosol into the mitochondria for energy production via beta-
oxidation. Physiologically, almost all free carnitine is intracellular
(Cave et al, 2008) and the renal absorption rate is high (Bellinghieri
et al, 2003). Interestingly, two urinary NMR studies report a trend
towards increased urinary levels of free carnitine HCC patients,
when compared with a healthy control or cirrhosis group (Table 6).
Since renal function was not assessed in any of the studies
considered in this review, and renal diseases, such as the
hepatorenal syndrome, are common secondary to cirrhosis and
HCC, increased urinary-free carnitine may indicate kidney
dysfunction, instead of being specific for HCC. Increased urinary
acylcarnitines (esterified acyl groups with carnitine) have been
reported in specific FFA oxidation disturbances and after extensive
workout (Flanagan et al, 2010). Urinary acetylcarnitine, however,
has not been associated with HCC before and may therefore be a
specific HCC biomarker candidate.
The differential serum levels of carnitines, when HCC is
compared to a healthy control cohort, seem to exhibit a specific
pattern, with mostly increased free carnitine levels, decreased short
to medium-chain acylcarnitines and increased levels of long-chain
acylcarnitine C18 : 1 and C18 : 2. A major role of short- and
medium-chain acylcarnitines is to remove organic acids from
organelles such as mitochondria, and eventual excretion in urine
and bile. The decrease in serum, however, indicates either an
increased excretion rate or a decreased accumulation rate. In
contrast, long-chain acylcarnitines are formed intracellularly for
the purpose of energy production. Therefore, elevated long-chain
acylcarnitine levels could possibly permit an increased FFA
transport into mitochondria and hence increase energy production.
The interpretation of these findings should be taken with
caution, since carnitine levels can be influenced by many other
factors, such as by diet, renal dysfunction or altered biosynthesis
rates. Blood acylcarnitines levels may also be influenced by the
hepatic fatty acid metabolism, that is, increased (or decreased)
acylcarnitine levels due to the increased (or decreased) production
of acyl groups in the liver or other tissues.
There is a body of evidence that patients with different cirrhosis
aetiologies show specific carnitine profiles. For instance, when
compared to healthy volunteers, patients with viral hepatitis-
induced cirrhosis (HBV and HCV) showed an increase in plasma
long-chain acylcarnitines, whereas patients with alcohol-induced
cirrhosis had elevated levels of both, long- and short-chain
acylcarnitines (Kra¨henbu¨hl, 1996). Clinical studies on L-carnitine
and acetyl-L-carnitine as a dietary supplement found positive
effects on cognitive function (Malaguarnera, 2012), indicating that
treatment with carnitine may provide useful information on energy
metabolism in cirrhosis and HCC.
Increased urinary and plasma carnitine and acylcarnitine levels
have also been described in kidney diseases (Calabrese et al, 2006;
Ganti et al, 2012) and in patients treated with certain chemother-
apeutic drugs, such as cisplatin (Dodson et al, 1989; Heuberger
et al, 1998).
Energy, nucleotide, and amino acid metabolism. Other energy
metabolism-related compounds found to be discriminatory
between HCC and healthy cohorts include 2-oxoglutarate,
succinate, and glycerol (Table 7). The elevation of 2-oxoglutarate,
a key component of the TCA cycle, may be a consequence from a
decreased mitochondrial respiration, that is, the Warburg effect.
This hypothesis is strengthened by tissue metabolomics studies
Table 5. Discriminative FFAs between HCC and comparison groups
HCC: Healthy HCC: Cirrhosis
Compound HMDB ID Association Serum Urine Serum Urine
FFA C24 : 1 (nervonic acid) 02368 Lipid metabolism/energy
metabolism
k (Chen et al, 2011b; Patterson et al, 2011)
Oleamide 02117 Lipid metabolism/energy
metabolism
k (Chen et al, 2011b)
m (Wang et al, 2012)
k (Wang et al, 2012;
Xiao et al, 2012)
FFA C16 : 0 (palmitic acid) 00220 Lipid metabolism/energy
metabolism
k (Chen et al, 2011b)
m (Zhou et al, 2012b)
 (Xue et al, 2008)
FFA C18 : 0 (stearic acid) 00827 Lipid metabolism/energy
metabolism
k (Chen et al, 2011b)
m (Zhou et al, 2012b)
 (Xue et al, 2008)
FFA C20 : 4 (arachidonic acid) 01043 Lipid metabolism/energy
metabolism
k (Chen et al, 2011b)
m (Zhou et al, 2012a, Zhou et al, 2012b)
Abbreviations: FFAs¼ free fatty acids; HCC¼hepatocellular carcinoma; HMDB¼The Human Metabolome Database. k indicates decrease in HCC; m indicates increase in HCC;  indicates not
reported whether decreased or increased.
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that report glycolytic phenotypes of HCC (Huang et al, 2013).
Contradictory urinary concentrations were reported for succinate,
another TCA intermediate. A factor that may convolve the
biological signal in urinary metabolite profiles is the extent of
which a urinary metabolite concentration reflects the metabolite’s
blood concentration. Although the urinary metabolome is a subset
of the total body metabolome, urinary metabolite concentrations
depend on the renal excretion rate, which is metabolite specific and
tightly regulated, depending on many factors such as blood pH.
Evidence that supports this hypothesis is given in Chen et al, 2011b
and Bouatra et al, 2013. Furthermore, a number of amino acids
were found to discriminate between HCC and healthy controls in
serum and/or urine. An amino acid imbalance has been recognised
previously in the serum of patients with CLD; specifically the
decrease in branched chain amino acids (BCAAs: leucine,
isoleucine, and valine) and the increase in aromatic amino acids
(AAAs: phenylalanine, tryptophan, tyrosine, and histidine); in
particular tyrosine (Michitaka et al, 2010). This mainly has been
supported by a metabonomic study, with an exception of
phenylalanine, which was found increased in the sera of HCC
patients, when compared to healthy controls. Decreased serum
BCAAs may also be linked to elevated serum carnitine levels, since
they are able to oxidise BCAAs (Hoppel, 2003).
In addition, the urinary concentration of the purine nucleoside
hypoxanthine has been found to be significantly higher in HCC
when compared to healthy individuals. However, another study
reports a decreased urine concentration, potentially due to the
different HCC aetiologies of the cohorts. A tissue metabonomic
study reported increased hypoxanthine concentrations in HCC
tissue, compared to matched non-tumourous tissue of HCC
patients (Huang et al, 2013).
Other relevant metabolites, shown to be reduced in the urine of
HCC patients, include creatinine and trimethylamine-N-oxide
(TMAO). Urinary creatinine excretion is related to muscle mass
(Oterdoom et al, 2009) and therefore may be a manifestation of
cancer cachexia, instead of being specifically HCC related.
Trimethylamine-N-oxide is generated in the liver from oxidation
of the gut microbiota co-metabolite trimethylamine (TMA) by
flavin monooxygenases. The production of TMA by the human gut
microbiota may represent a link between HCC and interactions of
host – gut microbiota, which have previously been suggested to
have the capacity to promote hepatocarcinogenesis (Mederacke
et al, 2012). In addition, increased TMAO levels may be partially
responsible for decrease of serum bile acids, since TMAO is
involved in cholesterol metabolism (Koeth et al, 2013).
Diagnostic performance of metabolite biomarker candidates.
From 22 studies reviewed, only 6 assessed the diagnostic
performance of the biomarker candidates proposed (Xue et al,
2008; Chen et al, 2011a; Wang et al, 2012; Zhou et al, 2012a;
Baniasadi et al, 2013; Huang et al, 2013). However, the
performance of these metabonomic models to detect and
differentiate HCC from healthy volunteers or cirrhosis patients is
consistently better than the performance of AFP. The model with
the best performance in discriminating HCC from cirrhosis cohort
was constructed with full-serum LC-MS data (without variable
selection), yielding 100% sensitivity and specificity (ROC¼ 100%;
Wang et al, 2012). A heavily reduced model, constructed with only
canavaninosuccinate and AFP, achieved a sensitivity and specificity
of 96.4 and 100%, respectively (Wang et al, 2012). Another high-
performance model for the discrimination between HCC and
cirrhosis patients was obtained with acetylcarnitine C3 (propio-
nylcarnitine) and betaine, yielding in an AUC of 0.98 (Huang et al,
2013). A comparably high ROC value was obtained for a four-
compound PLS-DA model for the discrimination between HCV
infected cirrhosis patients with and without HCC, including
methionine, 5-hydroxymethyl-20-deoxyuridine, N2,N2-dimethyl-
guanosine and uric acid (Baniasadi et al, 2013). The best model
performance for the discrimination between HCC and healthy
controls was based on serum levels of 1-methyladenosine
combined with AFP, yielding in an AUC of 0.95 (Chen et al,
2011a). Very similar, in terms of performance, but without AFP
was a model that included endocannabinoids anandamide and
palmitylethanolamide yielding in an AUC of 0.94 (Zhou et al,
2012a). The same model was used to discriminate between HCC
and cirrhotics with an AUC of 0.88. A different model that
Table 6. Discriminative carnitines between HCC and comparison groups
HCC: Healthy HCC: Cirrhosis
Compound HMDB ID Association Serum Urine Serum Urine
Carnitine 00062 Energy metabolism m (Yin et al, 2009;
Chen et al, 2011b)
k (Zhou et al, 2012b;
Huang et al, 2013)
m (Chen et al, 2009;
Shariff et al,
2010, 2011)
m (Shariff et al, 2010, 2011)
Acetylcarnitine 00201 Energy metabolism m (Yin et al, 2009)
k (Zhou et al, 2012b)
Acylcarnitine C3 : 0 00824 Energy metabolism k (Zhou et al, 2012b;
Huang et al, 2013)
Acylcarnitine C8 : 0 00791 Energy metabolism k (Zhou et al, 2012b;
Chen et al, 2013a)
Acylcarnitine C8 : 1 00791 Energy metabolism k (Zhou et al, 2012b;
Chen et al, 2013a)
Acylcarnitine C10 : 0 00651 Energy metabolism k (Zhou et al, 2012b;
Chen et al, 2013a)
Acylcarnitine C10 : 1 13205 Energy metabolism k (Zhou et al, 2012b;
Chen et al, 2013a)
Acylcarnitine C18 : 1 13338 Energy metabolism m (Zhou et al, 2012a, b;
Chen et al, 2013a)
k (Xiao et al, 2012)
m (Zhou et al, 2012a)
Acylcarnitine C18 : 2 13212 Energy metabolism m (Zhou et al, 2012a, b;
Chen et al, 2013a)
k (Xiao et al, 2012;
Zhou et al, 2012a)
Abbreviation: HBV¼ hepatitis B virus; HCC¼ hepatocellular carcinoma; HMDB¼The Human Metabolome Database. k indicates decrease in HCC; m indicates increase in HCC; w indicates
control group of the study (Huang et al, 2013) comprised chronic HBV carriers.
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included 13 serum components had an overall accuracy of 75% in
discriminating HCC from healthy controls (Xue et al, 2008). Only
one urinary study evaluated the performance of an established
PCA model for discriminating between HCC patients and healthy
controls. Their model included 18 urinary compounds plus serum
AFP and performed much better than AFP, with an AUC of 0.928
(Wu et al, 2009). Taken together, these models seem to suggest that
a robust diagnostic of HCC could be produced with a reduced
panel of biomarkers rather than using the whole spectroscopic
dataset. However, given that the panels of biomarker thus far
reported in the literature have not been assessed in independent
validation cohorts, there is now a pressing requirement for driving
a full validation study for a selected biomarker panel.
HCC markers proposed by MS-based proteomics
State of the science. The PubMed search conducted using the
search term stated in the Methods section resulted in the selection
of 171 references. These were initially screened by methodology
and all publications not utilising MS as a primary discovery
approach were filtered out. The remaining references were read for
adherence to the specified inclusion criteria leading to the
exclusion of a further 31, leaving 29 to be used in this paper.
Early studies applying MS techniques to clinical proteomics
biomarker research exerted a greater focus on the utilisation of
SELDI/MALDI ionisation platforms, occasionally coupled with
weak/strong ion-exchange chromatography techniques for the
identification of protein marker candidates. The MS analysis was
typically applied in concert with two-dimensional electrophoresis
methods where proteins separated according to their isoelectric
points and molecular weights were observed on a global scale.
Notable points of differentiation in spot patterns correlating with
disease groupings would be excised for identification following in-
gel digestion. Alternative approaches to marker discovery, which
have since become more popular include untargeted analyses using
tandem MS fragmentation methods to break up chromatographi-
cally separated proteins expressed in clinical samples followed by
database-driven identification (Nesvizhskii, 2007). Both these
approaches are applicable to pre-fractionated or un-fractionated
Table 7. Additional metabolites associated with TCA cycle, and protein and nucleotide metabolism
HCC: Healthy HCC: Cirrhosis
Compound HMDB ID
Association/
compound class Serum Urine Serum Urine
Isoleucine 00687 AA/protein synthesis k (Chen et al, 2013a)
 (Xue et al, 2008)
Leucine 00687 AA/protein synthesis k (Chen et al, 2011b, 2013a)
Methionine 00696 AA/protein synthesis k (Chen et al, 2011b; Huang et al, 2013) w)
m (Chen et al, 2013a)
Phenylalanine 00159 AA/protein synthesis k (Chen et al, 2011b)
m (Gao et al, 2009; Wang et al, 2012; Zhou
et al, 2012a; Chen et al, 2013a)
k (Wang et al,
2012; Zhou et al,
2012a; Baniasadi
et al, 2013)
Threonine 00167 AA/protein synthesis m (Wu et al, 2009;
Chen et al, 2011b)
Tryptophan 00929 AA/protein synthesis k (Chen et al, 2011b, 2013a; Zhou et al,
2012a, b)
Tyrosine 00158 AA/protein synthesis m (Gao et al, 2009; Chen et al, 2013a)
k (Chen et al, 2011b)
m (Wu et al, 2009;
Chen et al, 2011b)
Valine 00883 AA/protein synthesis k (Gao et al, 2009; Chen et al, 2013a)
m (Wei et al, 2012) w
Creatinine 00562 Alanine and proline
metabolism
k (Chen et al, 2011b; Wei et al, 2012) w k (Chen et al,
2009; Shariff et al,
2010, 2011)
m (Shariff et al,
2010, 2011)
Choline 00097 Lipid metabolism m (Wei et al, 2012) w)
k (Gao et al, 2009)
Glycerol 00131 Lipid metabolism/
energy metabolism
k (Chen et al, 2011b)
m (Gao et al, 2009)
 (Xue et al, 2008)
Trimethylamine N-oxide 00925 Microbial
co-metabolite
k (Shariff et al,
2011; Chen et al,
2011b)
Creatine 00064 Other k (Chen et al,
2011b)
m (Shariff et al,
2010, 2011)
Hypoxanthine 00157 Purine nucleoside k (Wu et al, 2009)
m (Chen et al,
2009, 2011b)
2-Oxoglutarate 00208 TCA cycle m (Gao et al, 2009, Chen et al, 2011b)
Succinate 00254 TCA cycle k (Wu et al, 2009;
Chen et al, 2011b)
Abbreviation: AA¼ amino acid; HBV¼ hepatitis B virus; HCC¼ hepatocellular carcinoma; HCV¼hepatitis C virus; HMDB¼The Human Metabolome Database; TCA¼ tricarboxylic acid.
k indicates decrease in HCC; m indicates increase in HCC; w indicates control group of the study (Huang et al, 2013; Wei et al, 2012) comprised chronic HCV or HBV carriers, respectively.
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samples as well as those which have undergone pre-enrichment
steps for particular post-translational modifications (PTMs) of
interest; a major form of this being glycosylation changes. This
general shift from the coupling of gel-based classical proteomic
approaches with MS to standalone chromatography-MS platforms
has enabled researchers a greater detail in the analysis of the
human proteome as well as increased flexibility and unmatched
depth in finding biomarker targets.
Protein families. Proteomic exploration using MS is widely
focussed on serum and plasma, which form the key body fluids
with the greatest dynamic range of protein expression. This review
of protein markers for HCC determined by MS in various
populations identifies candidates from a wide range of protein
families. Acute-phase and transport proteins, enzymes as well as
proteins involved in various complementary and lipid metabolic
pathways form some of the most commonly reported classes of
biomarker candidates. Alongside these, a smaller number of
proteins involved in numerous functions ranging from apoptosis,
ion transport, host immunity, iron homoeostasis, protection from
toxins and oxidative stress, cell adhesion, differentiation, regenera-
tion, and death are reflected in the list of reported markers
(Table 8). As the most frequently proposed protein subtype for
biomarker candidates, the suggestion of acute-phase proteins as
biomarker candidates is often eyed with scepticism as they are seen
to lack specificity for particular disease processes. These proteins,
however, constitute a well validated subset of proposed markers
suggested from experiments run on numerous MS platforms in the
context of HCC and CLDs. A1AT and alpha-1-antichymotrypsin
(AACT) are major acute-phase proteins, which serve as protease
inhibitors protecting tissues from the enzymatic action of
inflammatory cells. Five independent publications identified these
proteins as elevated in HCC patients; with a highest reported fold
change of 5.3. Another large subset of proteins often reported
following MS interrogation of HCC samples are apolipoproteins.
These are proteins that bind lipids and cholesterols in the blood
and lymphatic systems. Several isoforms, namely Apo A1, Apo J,
Apo L1, and Apo B-100 have been consistently reported as
downregulated in HCC. In particular, Apo J in its association with
HCC has been implicated as a possible indicator of the metastatic
potential of primary tumours (Lau et al, 2006). In overall
performance reports, some of the most consistently highlighted
proteins include those with functional properties such as ion
transport and scavenging, in particular – iron homoeostasis.
Haptoglobin and haemopexin are key players in the maintenance
of haemoglobin and free haem in the blood. Haptoglobin binds
free haemoglobin with high affinity and thus protects cells from its
oxidative effects. Haemopexin on the other hand binds free haem
released in the turnover of erythrocytes and preserves the body’s
iron stores. Like most of the proteins with unique expression
trends concordant with liver disease, the specific mechanisms
linking these proteins to CLD are not understood. However,
amalgamated reports demonstrate that haptoglobins are largely
increased in blood from HCC patients. Haemopexin in its whole
and fucosylated forms follow the same trend with a suggestion in
one report of a decrease in LC (Fye et al, 2013).
Challenging discrepancies. This review identifies 31 individual
proteins as showing differential signatures associated with a stage
of liver disease. Each of these have undergone at least one level of
validation whether in the context of the same publication or in an
independent report. Overall, the direction of the alterations in
protein expression are uniform, there however are some specific
proteins, namely alpha-1-acid glycoprotein, afamin, complement
component 3, and haptoglobin-related protein that demonstrate
discrepancies in behaviour in selected case–control groupings.
Alpha-1-acid glycoprotein, for example, is reported to be down-
regulated in HCC’s in comparison to cirrhotics by one group (Lee
et al, 2011) and upregulated in HCC’s vs LC’s by another (Kang
et al, 2010). Complement component 3 shows a similar
discrepancy in two studies (Steel et al, 2003; Ahn et al, 2012b).
In each of these cases, key differences related to HCC assessment,
sample pretreatment and MS platform used are likely contributors
to the lack of consistency observed. Numerous publications
included in this review and directly implicated in these discrepant
examples have little to no clinical information on how LC or HCC
cases were diagnosed (Ishihara et al, 2011; Ahn et al, 2012b), not to
mention an almost uniform lack of staging data. For proteomic
analyses in particular, different approaches exist to sample
pretreatment, with options to deplete key abundant proteins,
enrich for, or exclude (Lee et al, 2011) particular PTMs. With
albumin constituting B60% of the total protein content of blood
(Shen et al, 2004) and forming the backbone of many protein–
protein interactions and complexes, its depletion could contribute
to the loss of important endogenous signatures. Varying depletion
protocol efficiencies may also impact directly on the accuracy of
downstream quantitation. Additional separation by isoelectric
or electrophoretic analysis according to molecular weight or
isoelectric point whether ‘in’ or ‘off-gel’ can be applied to neat or
pre-treated samples meaning that the final matrix injected into the
MS instrument may already be severely biased towards identifica-
tion of selected protein subtypes or sizes. This phenomenon along
with varying MS platforms and ionisation methods will all
contribute to the differences observed in shortlisted marker
profiles at final analyses. Thus, the quantitative data assembled,
though important cannot always be taken as conclusively reflective
of endogenous expression. This can only be adequately assessed by
targeted measurement of whole proteins using highly specific
antibody-based methods or absolute quantitation by S/MRM MS
analysis of unique peptide sequences in well-characterised sample
cohorts.
Glycosylation and HCC. An area of particular focus in terms of
identifying unique exploitable changes for differential CLD
diagnosis are those which occur in the glycosylation of many
proteins during liver disease progression (Blomme et al, 2009).
Glycosylation is essential to the tertiary and quaternary structures
of many proteins bearing direct impact on their solubility and
transport. The carbohydrate moieties bound to these modified
proteins can be directly impacted by changes in host immunity and
carcinogenesis. The surface of hepatocytes contain various
receptors that bind proteins via their carbohydrate groups; when
changes to the liver surface occur as a result of fibrosis, cirrhosis, or
HCC, alterations in receptor distribution can lead to the
accumulation of certain glycoproteins in the blood, which can be
picked up by methods such as MS. As asparagine-linked (N-linked)
glycosylation is the predominant form found in human sera, much
research has been focussed on this particular subclass of
glycoproteins. Investigations looking at the glycosylation patterns
of key serum proteins associated with HCC and LC reports
evidence of hyperfucosylation for 19 glycoproteins (Comunale
et al, 2006) in the context of liver disease. Mass spectrometric
assays conducted on lectin-enriched samples are seen to represent
a sizable fraction of the protein markers identified in this review.
Fucosylated haemopexin stands out as one of the highest
performing candidate markers for HCC diagnosis with a reported
AUC of 0.95 (Comunale, 2009). Numerous additional publications
using lectin enrichment steps prior to MS analysis have identified
various glycosylated proteins such as alpha-1-acid glycoprotein 1
(A1AG1), AACT, Apo L1, Apo J (Ahn et al, 2012a, b), and several
complement proteins as differentially expressed in HCC vs other
disease stages. The multiply reported decline in the blood levels of
various isoforms of the apolipoproteins involved in lipid and
cholesterol metabolism have also been demonstrated to hold
significant association with HCC.
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Table 8. Summary of proteomic studies that were reviewed
Protein (key
role)
UniProt
ID Biofluid
Relation
to HCC
(m, k)
HCC LB
rate Cohort sizes Aetiology AUROC
Fold
change Platform Reference
AGP1 (AP:
Transport)
P02763 Plasma m HCC:CON No information *10 HCC; 30 controls (healthy/
LC/HBV)
HBV 0.73 1.6* Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b*
Plasma k HCC:LC No information Disc: 10 HCC/2 HCON
Val: 18 HCC, 10 HCON
No
information
0.65 — nUPLC–ESI–
QTOF–MS and
QQQ
Lee et al,
2011
Serum m HCC:LC 100% ALL Disc: 9 HCC/9 LC
Val: 52 HCC/40 LC
HBV — 1.8w ICAT–LC–ESI–
MS/MS
Kang et al,
2010
A1AT (AP:
Protease inhibitor)
P01009 Plasma m HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
0.84 — QTOF–LC–MS,
ELISA
Fye et al,
2013
Plasma m HCC:CON No information *10 HCC; 30 controls (healthy/
LC/HBV)
HBV 0.92 2.4** Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b*
Serum m HCC:CON No information Disc: 20 HCC, 20 HBV, 20 HCON
Val: 20 HCC, 20 HBV, 20 HCON
HBV — — MALDI–TOF–
MS/MS, 2DE
Feng et al,
2005
A2M (Protease
inhibitor)
P01023 Plasma m HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC,
120 HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 1.13* QTOF–nUPLC–
ESI–MS
Fye et al,
2013
Serum k HCC:LC 100% of HCCs Disc: 9 HCC/9 LC
Val: 52 HCC/40 LC
HBV — 0.26w ICAT–LC–ESI–
MS/MS
Kang et al,
2010
AACT (AP:
Protease inhibitor)
P01011 Plasma m HCC:CON No information *10 HCC; 30 controls (healthy/
LC/HBV)
HBV 0.93 3.7** Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b*
Plasma m HCC:CON No information 6 HCC, 3 HCON No
information
— 5.3* 2D LC–MALDI–
TOF/TOF
Ishihara
et al, 2011
AFM (Vitamin
transport)
P43652 Plasma m HCC:CON No information 6 HCC, 3 HCON No
information
— 33.1w 2D LC–MALDI–
TOF/TOF
Ishihara
et al, 2011
Plasma k HCC:CON No information 28 HCC, 10 HCON No
information
0.72 — nUPLC–ESI–
QTOF–MS and
QQQ
Lee et al,
2011
Apolipoproteins
Apo A1
(Cholesterol
metabolism)
P02647 Plasma k HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
0.83 — QTOF–nUPLC–
ESI–MS
Fye et al,
2013
Serum k HCC:CON 100% of HCCs 20 HCC, 20 HCON No
information
—  3.59* 2DE-coupled
MALDI–TOF–
MS
Sun et al,
2010b
Serum k HCC:CON 100% of HCCs 8 HCC, 21 HBV, 7 HCON HBV — 3.10w 2DE-coupled
MALDI–TOF–
MS
Steel et al,
2003
Apo B-100
(Cholesterol
metabolism)
P04114 Plasma k HCC:CON No information 6 HCC, 3 HCON No
information
— 3.7* 2D LC–MALDI–
TOF/TOF
Ishihara
et al, 2011
Apo L1
(Cholesterol
metabolism)
O14791 Plasma k HCC:CON No information *10 HCC; 30 controls (healthy/
LC/HBV)
HBV 0.68 0.5ns Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b*
B2M (Immunity) P61769 Plasma m HCC:CON No information 6 HCC, 16 LC/HBV/HCV, 8
HCON
HCV/HBV — — SELDI–TOF–MS Nakatsura,
2010
Serum mHCC:pre-
HCC
Some Histo. %
not stated
38 Pre-HCC; 35 samples upon
clinical diagnosis of HCC; 18
samples post treatment
(longitudinal collection)
HCV — 1.82** SELDI–TOF–MS Ward et al,
2006
C4B-a
(Complement
pathway)
P04003 Plasma m HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 1.25ns QTOF–nUPLC–
ESI–MS
Fye et al,
2013
m HCC:CON No information *10 HCC; 30 HCON/LC/HBV HBV 0.66 1.3ns Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b*
CC3
(Complement
pathway)
P01024 Plasma m HCC:CON No information 10 HCC; 30 HCON/LC/HBV HBV 0.67 2.0ns Lectin MRM–
ESI–UPLC–MS
Ahn et al,
2012b
Plasma m HCC:LC Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC,
10 HCON
HBV/
aflatoxin
0.70 — QTOF–nUPLC–
ESI–MS, ELISA
Fye et al,
2013
Serum k HCC:CON 100% of HCCs 8 HCC, 21 HBV, 7 HCON HBV —  1.87** 2DE-coupled
MALDI–TOF–
MS
Steel et al,
2003
CC3-a Serum mHCC:CLD/
CON
No LBs done 45 HCC, 42 CLD, 21 HCON HCV 0.70 — SELDI–TOF–MS Kanmura
et al, 2010
mHCC:CLD/
CON
No information 28 HCC, 10 HCON HCV — n/r but
P of D
0.00001
SELDI–TOF–
MS, WB
Lee et al,
2006
BRITISH JOURNAL OF CANCER
1150 www.bjcancer.com |DOI:10.1038/bjc.2015.38
Table 8. ( Continued )
Protein (key
role)
UniProt
ID Biofluid
Relation
to HCC
(m, k)
HCC LB
rate Cohort sizes Aetiology AUROC
Fold
change Platform Reference
CERU (Cu/ion
transport)
P00450 Plasma m HCC:CON No information 10 HCC; 30 HCON/LC/HBV) HBV 0.77 1.5** Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012b
Plasma m HCC:CON No information 6 HCC, 3 HCON No
information
— 6.8w 2D LC–MALDI–
TOF/TOF
Ishihara
et al, 2011
Serum HCC only 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — nanoHPLC–ESI–
MS/MS
Yang et al,
2007a
Serum m HCC:CON No information Disc: 20 HCC, 20 HBV, 20 HCON
Val: 20 HCC, 20 HBV, 20 HCON
HBV — — 2DE and
MALDI–TOF–
MS/MS
Feng et al,
2005
CLU (apoptosis/
complement
pathway)
P10909 Plasma/
serum
k HCC:CON No information No information No
information
— — SID–MRM–MS Zhao et al,
2010
Plasma k HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 0.59* QTOF–nUPLC–
ESI–MS
Fye et al,
2013
Plasma k HCC:CON No information 10 HCC; 30 HCON/LC/HBV HBV 0.70 0.8ns Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012a, b
Serum m HCC:CON No information Disc: 20 HCC, 20 HBV, 20 HCON
Val: 20 HCC, 20 HBV, 20 HCON
HBV — — 2DE and
MALDI–TOF–
MS/MS
Feng et al,
2005
ERBB3 (Signalling
pathway)
P21860 Serum mHCC:LC/
CON
Disc and Val 1–
100%
Val 2; Unclear
Disc: 10 total, HCC and non-
HCC
Val 1: 113 HCC, 47 LC, 64 HBV/
HCV
Val 2: 57 HCC, 35 HBV/HCV
HBV/HCV 0.93/0.71 — MALDI–TOF–
MS, WB, ELISA
Hsieh et al,
2011
GFAP (cell
differentiation/
regeneration)
P14136 Serum m HCC:CON 100% HCCs Disc: 20 HCC, 20 HCON
Val: 5 HCC, 5 HCON
No
information
— — 2DE-coupled
MALDI–TOF,
WB
Wu et al,
2012
hCE1 (response to
toxins)
P23141 Plasma m HCC:CON No information 24 HCC, 14 LC, 7 CH, 8 CCa, 15
stomach cancer, 16 pancreatic
cancer
No
information
0.80 — 2DE MALDI–
TOF/TOF,
nano-LC MS/
MS, WB
Na et al,
2009
HP (AP: Immunity
and Fe
homoeostasis)
P00738 Serum m HCC:CON 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — 2DE LC–ESI–
MS/MS
Yang et al,
2007a
Serum m HCC:CLD 100% of HCCs 56 HCC, 40 CLD No
information
0.73 2.57** ELISA Ang et al,
2006
Serum m HCC:CON No information Disc: 20 HCC, 20 HBV, 20 HCON
Val: 20 HCC, 20 HBV, 20 HCON
HBV — — 2DE and
MALDI–TOF–
MS/MS
Feng et al,
2005
Serum m HCC:CON 100% of HCCs 20 HCC, 20 HCON No
information
— 5.10** 2DE-coupled
MALDI–TOF–
MS
Sun et al,
2010b
Plasma m CON:LC Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 1.35* QTOF–nUPLC–
ESI–MS
Fye et al,
2013
HPR (metabolic
process)
P00739 Serum m HCC:CON 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — 2DE LC–ESI–
MS/MS
Yang et al,
2007a
Plasma k HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 0.65* QTOF–nUPLC–
ESI–MS
Fye et al,
2013
HPX (Fe
homoeostasis)
P02790 Plasma m HCC:CON No information 10 HCC; 30 HCON/LC/HBV HBV 0.61 1.2ns Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012b
Plasma m CON:LC Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
0.81 — QTOF–nUPLC–
ESI–MS
Fye et al,
2013
Fu-HPX Plasma m HCC:CON Some Histo. %
not stated
72 HCC, 32 LC, 33 HBV, 133
HCV, 62 other liver diseases, 20
CON
HCV/HBV 0.95 1.4** Lectin LC–MS/
MS
Comunale,
2009
HSP90 (stress
response)
P08238 Serum m HCC:CON 100% of HCCs 20 HCC, 20 HCON No
information
— 7.04** MALDI–TOF–
MS, ELISA
Sun et al,
2010b
OPN
(biomineralisation/
cell adhesion)
P10451 Plasma mHCC:CLD/
CON
Val: None Disc: 17 HCC, 18 LC
Val: 131 HCC, 76 LC, 52 CHCV/
HBV, 53 HCON
HCV/HBV 0.76 — LC–ESI–MS/MS
with 2D nHPLC-
coupled LTQ
OrbiTrap
Shang et al,
2012
Plasma mHCC:CON/
LC
Some Histo. %
not stated
30 HCC, 30 LC, 20 HCON HCV 0.92 4.33w ELISA El-Din
Bessa et al,
2010
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Critical assessment and performance comparisons. In the
presentation of candidates as potential biomarkers for HCC or
any other condition; there has to be a widely applicable tool of
measurement offering universal assessment of the potential
usefulness and validity of a marker. Area under the curve reports
with its achievable sensitivity and specificity at a chosen cut-off and
fold change statistics form the most widely employed tools, and
have become the benchmarks used for comparative assessment of
candidates. Few studies report both AUC and fold change statistics
as is seen in the comprehensive tables presented (Tables 2 and 8).
As AFP is the only established non-invasive tool used for HCC
diagnosis – all biomarker studies are in effect in competition with
its performance. One major gap, which exists in making
comparative assessments with AFP within and across studies is
that oftentimes the test forms an intrinsic part of the initial
diagnostic profile used to classify subjects into the various clinical
groups under evaluation. Without direct comparison of AFP and
the gold standard in HCC diagnosis of liver biopsy within the same
subject populations, no true evaluation of AFP performance can be
accepted as an accurate reference point. In the absence of this, most
publications are either mute on this point or address it by basing
their performance evaluations on reported estimates for AFP
performance often ranging between 0.6 and 0.7 with some dipping
lower (Giannini et al, 2012).
DISCUSSION AND CONCLUSION
This review serves as a focus for summarizing and highlighting
metabonomic and proteomic literature on biomarkers for HCC in
the urine and blood. A multitude of biomarker candidates have
been proposed by comparative 1H NMR or MS analysis of urine
and/or blood from HCC patients and various CLD groups. A
review of these studies has shown that noteworthy changes occur at
both the metabolite and protein levels, which correlate with disease
aetiology and/or progression. Of significant note however are the
multitudes of candidates, which do not appear to be reproducible
but nevertheless weigh heavily on literature reports. These are vast
in number and were filtered from this review, as they detracted
from its stated aims. In order to move forward and accelerate the
conversion of biomarker candidates into routine and robust tests to
be used in clinics and the field, particularly in the developing
world, this area of research must be held to a minimum standard of
uniformity (Table 9) and from this facilitate a momentum shift
Table 8. ( Continued )
Protein (key
role)
UniProt
ID Biofluid
Relation
to HCC
(m, k)
HCC LB
rate Cohort sizes Aetiology AUROC
Fold
change Platform Reference
PON-1
(antioxidant/
hydrolase)
P27169 Serum m HCC:CON 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — 2DE LC–ESI–
MS/MS
Yang et al,
2007a
Plasma k HCC:CON Disc 24.2%
Val 4.8%
Disc: 120 HCC, 99 LC, 120
HCON
Val: 21 HCC, 6 LC, 18 ASC, 10
HCON
HBV/
aflatoxin
— 0.63** QTOF–nUPLC–
ESI–MS
Fye et al,
2013
Prx-II (antioxidant/
oxidoreductase/
peroxidase)
P32119 Plasma m LC:CON 100% of cases Disc: 27 HBV, 7 HCON
Val: 68 HBV, 42 HCON
HBV 1.00 — MALDI–TOF–
MS
Lu et al,
2010
Tissue m HCC:CON 100% of HCCs 6 HCC, 6 non-malignant
adjacent tissue
HBV — 2.1w 2DE-coupled
MALDI–TOF–
MS
Matos et al,
2009
SAA (AP and
innate response/
cell adhesion)
P0DJI8 Serum m HCC:CON No information 67 HCC, 53 CHBV, 44 HCON HBV — 4.5w 2DE MALDI–
TOF–MS,
SELDI–TOF–MS
He et al,
2008
Serum HCC only 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — 2DE LC ESI–
MS/MS
Yang et al,
2007a
SGP-2 (cell death) Q6LDQ3 Serum m HCC:CON 100% HCCs Disc: 20 HCC, 20 HCON
Val: 5 HCC, 5 HCON
No
information
— — 2DE MALDI–
TOF–MS, WB
Wu et al,
2012
TGM2 (apoptosis/
transferase)
P21980 Tissue/
serum
m HCC:CON ALL: 100% of
HCCs
Tissue disc: 61 HCC, 61 adjacent
non-tumour tissue
Val: 109 HCC, 42 HCON
HBV/HCV — — LTQ–FT–MS/
MS, ELISA
Sun et al,
2008
TTR (Transport) P02766 Serum k HCC:CON No information Disc: 20 HCC, 20 HBV, 20 HCON
Val: 20 HCC, 20 HBV, 20 HCON
HBV — — 2DE and
MALDI–TOF–
MS/MS
Feng et al,
2005
Serum k HCC:CON 100% of HCCs 5 HCC, 5 HCON HCV/HBV — — 2DE LC–ESI–
MS/MS
Yang et al,
2007a
VIM (host-virus
interaction)
P08670 Tissue/
serum
mHCC:LC/
CON
Disc: 100% of
HCCs
Val: No
information
Disc (tissue): 40 HCC, 36 CON
Val: 88 HCC, 64 CON
HBV 0.69 3.27w 2DE MALDI–
TOF/TOF,
ELISA
Sun et al,
2010a
VIT (cell adhesion) P04004 Serum m HCC:LC 91% of HCCs 44 HCC, 38 LC No
information
0.85 — SELDI–TOF–MS Paradis
et al, 2005
Serum k HCC:CON No information 10 HCC, 10 HCON No
information
— — SID–MRM–MS Zhao et al,
2010
Plasma m HCC:CON No information 10 HCC; 30 HCON/LC/HBV HBV 0.54 1.1ns Lectin MRM–
UPLC–ESI–MS
Ahn et al,
2012b
Plasma k HCC:CON No information 28 HCC, 10 HCON No
information
0.98 — nUPLC–ESI–
QTOF–MS and
QQQ
Lee et al,
2011
Abbreviations: 2D¼ two dimensional; 2DE¼ two-dimensional electrophoresis; ASC¼ asymptomatic carrier; AUROC¼ area under receiver operating characteristics; CCa¼ cholangiocarcinoma;
CHBV/CHCV¼ chronic HBV or HCV; CLD¼ chronic liver disease; ELISA¼ enzyme-linked immunosorbent assay; ESI¼ electrospray ionisation; HBV¼hepatitis B virus; HCC¼ hepatocellular
carcinoma; HCON¼healthy control; HCV¼hepatitis C virus; Histo¼ histology; ICAT¼ isotope-coded affinity tag; LB¼ liver biopsy; LC¼ liquid chromatography; MALDI¼matrix-assisted laser
desorption/ionization; MRM¼multiple reaction monitoring; MS¼mass spectrometry; n/r¼ not recorded; nanoHPLC¼ nano high-performance liquid chromatography; nUPLC¼nano
ultra-performance liquid chromatography; QQQ¼ triple quadropole mass spectrometer; qTOF¼quadrupole time of flight; WB¼western blot; SELDI¼ surface-enhanced laser desorption/
ionization; TOF¼ time-of-flight. *Po0.05; **Po0.01; ns, non-significant; w, no P-value reported.
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from discovery to validation-based experiments. A noteworthy
example is a recently conducted imaging MS study, which
validated an altered phospholipid composition in HCC tumour
tissues by transcriptomic analyses, thereby identifying LPCAT1 as
a potential target molecule to inhibit HCC progression. A key
limitation identified from the amalgamation of these reports,
which is of particular significance in investigations targeting
metabolites is the limited availability of descriptive statistics such
as ROC analyses and fold change ratios offering quantitative
measures of assessing the performance of a putative marker. Also
missing in many studies are any efforts at validating the proposed
biomarkers in distinct population sets. In both the proteomic and
metabonomic papers reviewed,o15% of publications included any
attempts at independent validation of results. Without a consistent
ability to reproduce primary discovery results in diverse popula-
tions, biomarkers will not accelerate on the pipeline towards
serious consideration.
It is recognised that routine liver biopsy assessment of suspected
HCCs is not readily available in many populations where the
condition is endemic. The relevance of biopsy sample retrieval and
definitive tumour staging however, cannot be overstated. For any
new HCC diagnostic test to have a direct impact on reducing
mortality from end-stage liver disease, it must be able to discern
those at highest risk of progression to HCC from a background of
LC or fibrosis as well as reflect early changes in the liver related to
tumourigenesis. Most of the markers included in this review have
been proposed from heterogeneous case groups where considera-
tions such as background health of liver, tumour stage, and severity
of cirrhosis or fibrosis have not been assessed or are not reported.
Thus, when these candidates are proposed for validation studies,
accurate case profiles must be presented that clearly stratify HCC
stages in order to home in on how candidates perform in the
diagnostic groups most difficult to distinguish. Best practice would
warrant the clear and comprehensive distinction of these at the
discovery stage but this is yet to be reflected in current practice.
Some metabolites are correlated with the degree of cirrhosis or the
hepatic compensation status of patients. For example, the
metabolic profile of patients with small HCC tumours on a
background of severe cirrhosis differs significantly from late HCC
with minor background cirrhosis (Nahon et al, 2012b). Group
heterogeneity can thus bias results and impact directly on the range
of proteins, metabolites, or pathways detected as significantly
different. Such comprehensive descriptions and assessments are
largely absent from current HCC biomarker literature and must be
incorporated and prioritised in order to identify biomarker
signatures of the highest impact.
Although the majority of studies presented provide detailed
demographic data for participants, there was an observed lack of
consistency in which clinical indices were reported in published
works. Reports on liver biopsy rates and AFP levels are arguably of
primary relevance to any HCC biomarker studies yet figures for
these were present only in a fraction of papers. For AFP in
particular, the cut-off taken as indicative of HCC, where reported,
was still highly variable, ranging from 20 to 500 ngml 1
depending on the specific study population or chosen guidelines.
Alongside this, details on overall liver health, liver compensation
status, clinical chemistry tests (e.g., liver enzymes and bilirubin),
and the treatment status of participants were at best inconsistently
reported. The absence or lack of consideration of these key clinical
parameters will undoubtedly have significant implications on
participant selection and classification as well as the interpretation
of disease-specific signatures. Thus, a key recommendation to be
made following this review is the need for some degree of uniformity
in the rationale and level of detail forming the basis of case and
control selection. Providing detailed case definitions would reduce or
at least allow for the contextualisation of marked variations, which
exist in the selection of cohorts. This could perhaps contribute to a
wider overlap in identified proteins and metabolites associated with
CLDs across different investigative platforms and thus offer greater
consensus on which targets to validate.
In order to move some of the many suggested HCC biomarker
targets forward and accelerate their conversion into routine and
robust tests usable in clinics and the field, particularly in the
developing world, the momentum of research must now shift from
discovery to validation-based experiments – focused both on
expression level and mechanistic changes between clinically
distinct groups. The populations involved in these studies must
be well characterised to dissect biomarkers that are specific for
(early) HCC and if these are still valid, in the presence of cirrhosis
or other comorbidities. Below, we summarise key points that can
significantly bias the results of a biomarker study on HCC. At the
same time, we give recommendations, which with careful
consideration could raise the likelihood of successful conversion
of proposed biomarkers in the field of HCC research.
Table 9. Recommendations for future metabonomic and proteomic studies on HCC
Key point Recommendation
Use of published guidelines to inform
case definitions
CLD diagnosis should be made using agreed international guidelines (e.g., EASL and AASLD). New guidelines must
be developed/adapted for areas of HCC endemicity in the developing world
Measure of total protein expression Use commercial assays (e.g., QuantiPro BCA) to quantify and normalise total protein expression in sampled blood
Prandial state 8–12 h Pre-prandial
Physical exercise Should be avoided immediately prior to sample collection
Overall liver function Assessment of Child-Pugh score:
A: Hepatic compensated
B: Slightly decompensated liver state
C: Hepatic decompensated
Tumour size and nodularity Tumour staging, for example, TMN classification
Comorbidities Clinical assessment of cirrhosis in the background of HCC
Clinical assessment of renal impairment, for example, kidney function tests such as glomerular filtration rate (important
for urinary analyses)
Tumour size and nodularity Tumour staging, for example, TMN classification
Validation of the diagnostic model Inclusion of external validation cohorts, for example, early HCCs, different HCC aetiologies, and tumour controls
Performance assessment of the
diagnostic model
AUROC statistic, enables direct comparison to other models and AFP
Abbreviations: AASLD¼American Association for the Study of Liver Diseases; AFP¼ alpha-fetoprotein; AUROC¼ area under receiver operating characteristics; BCA¼bicinchoninic acid;
CLD¼ chronic liver disease; EASL¼European Association for the Study of the Liver; HCC¼ hepatocellular carcinoma; TNM¼ tumour, nodes, and metastasis.
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Although the consideration of these points and recommenda-
tions will not lead to uniform impact for all researchers in this field
due to the diversity of challenges faced, it is however important
that they are recognised as highly relevant and begin to be
discussed on a larger scale.
REFERENCES
Ahn YH, Ji ES, Shin PM, Kim KH, Kim YS, Ko JH, Yoo JS (2012a)
A multiplex lectin-channel monitoring method for human serum
glycoproteins by quantitative mass spectrometry. Analyst 137: 691–703.
Ahn YH, Shin PM, Oh NR, Park GW, Kim H, Yoo JS (2012b)
A lectin-coupled, targeted proteomic mass spectrometry (MRM MS)
platform for identification of multiple liver cancer biomarkers in human
plasma. J Proteomics 75: 5507–5515.
Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, Johnson PJ, Sung JJ
(2006) Study of serum haptoglobin and its glycoforms in the diagnosis of
hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 5:
2691–2700.
Baniasadi H, Gowda GA, Gu H, Zeng A, Zhuang S, Skill N, Maluccio M,
Raftery D (2013) Targeted metabolic profiling of hepatocellular carcinoma
and hepatitis C using LC-MS/MS. Electrophoresis 34: 2910–2917.
Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, Volle DH
(2013) Bile acids: from digestion to cancers. Biochimie 95: 504–517.
Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V (2003) Carnitine
and hemodialysis. Am J Kidney Dis 41: S116–S122.
Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno
GS (2012) Hepatocellualar carcinoma serum markers. Semin Oncol 39:
410–433.
Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM (2010) Prognostic
and diagnostic value of des-gamma-carboxy prothrombin in liver cancer.
Drugs News Perspect 23: 498–508.
Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A,
Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I
(2014) Hepatocellular carcinoma: novel molecular targets in
carcinogenesis for future therapies. Biomed Res Int 2014: 203693.
Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M,
Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I (2011)
Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy
prothrombin and squamous cell carcinoma antigen immunoglobulin M
complexes in hepatocellular carcinoma. Minerva Med 102: 363–371.
Beyog˘lu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour
JF, Idle JR (2013) Tissue metabolomics of hepatocellular carcinoma: tumor
energy metabolism and the role of transcriptomic classification.
Hepatology 58: 229–238.
Biondi A, Malaguarnera G, Vacante M, Berretta M, D’Agata V,
Malaguarnera M, Basile F, Drago F, Bertino G (2012) Elevated serum
levels of chromogranin A in hepatocellular carcinoma. BMC Surg 12
Suppl 1: S7.
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H (2009)
Alteration of protein glycosylation in liver diseases. J Hepatol 50:
592–603.
Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC,
Krishnamurthy R, Saleem F, Liu P, Dame ZT, Poelzer J, Huynh J, Yallou
FS, Psychogios N, Dong E, Bogumil R, Roehring C, Wishart DS (2013)
The human urine metabolome. PLoS One 8: e73076.
Boyle P, Levin B (2008) World cancer report 2008.
Bruix J, Sherman M. American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma: an update (2011) Hepatology
53: 1020–1022.
Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA (2006)
Acetylcarnitine and cellular stress response: roles in nutritional redox
homeostasis and regulation of longevity genes. J Nutr Biochem 17: 73–88.
Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ,
McClave SA (2008) Obesity, inflammation, and the potential application
of pharmaconutrition. Nutr Clin Pract 23: 16–34.
Chen F, Xue J, Zhou L, Wu S, Chen Z (2011a) Identification of serum
biomarkers of hepatocarcinoma through liquid chromatography/mass
spectrometry-based metabonomic method. Anal Bioanal Chem 401:
1899–1904.
Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F, Xu G (2009)
Metabonomics study of liver cancer based on ultra performance liquid
chromatography coupled to mass spectrometry with HILIC and RPLC
separations. Anal Chim Acta 650: 3–9.
Chen S, Kong H, Lu X, Li Y, Yin P, Zeng Z, Xu G (2013a) Pseudotargeted
metabolomics method and its application in serum biomarker discovery
for hepatocellular carcinoma based on ultra high-performance liquid
chromatography/triple quadrupole mass spectrometry. Anal Chem 85:
8326–8333.
Chen S, Yin P, Zhao X, Xing W, Hu C, Zhou L, Xu G (2013b) Serum lipid
profiling of patients with chronic hepatitis B, cirrhosis, and hepatocellular
carcinoma by ultra fast LC/IT-TOF MS. Electrophoresis 34: 2848–2856.
Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X,
Xu LX, Yen Y, Liu P, Jia W (2011b) Serum and urine metabolite profiling
reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell
Proteomics 10: M110 004945.
Chen Y, Xu Z, Kong H, Chen N, Chen J, Zhou L, Wang F, Dong Y, Zheng S,
Chen Z, Xu G, Li L (2012) Differences between the metabolic profiles of
decompensated and compensated cirrhosis patients with hepatitis B virus
infections under high-performance liquid chromatography-mass
spectrometry. Metabolomics 8(5): 845–853.
Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B,
Long RE, Junaidi O, Bisceglie AM, Block TM, Mehta AS (2009)
Identification and development of fucosylated glycoproteins as biomarkers
of primary hepatocellular carcinoma. J Proteome Res 8(2): 595–602.
Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S,
Evans AA, Hann HW, Block TM, Mehta AS (2006) Proteomic analysis of
serum associated fucosylated glycoproteins in the development of primary
hepatocellular carcinoma. J Proteome Res 5: 308–315.
Dodson WL, Sachan DS, Krauss S, Hanna W (1989) Alterations of serum and
urinary carnitine profiles in cancer patients: hypothesis of possible
significance. J Am Coll Nutr 8: 133–142.
El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH (2010) Clinical
significance of plasma osteopontin level in Egyptian patients with hepatitis
C virus-related hepatocellular carcinoma. Arch Med Res 41: 541–547.
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology 132: 2557–2576.
European Association for the Study of the LiverEuropean Organisation for
Research and Treatment of Cancer (2012) EASL-EORTC clinical
practice guidelines: management of hepatocellular carcinoma. J Hepatol
56: 908–943.
Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ,
Yang PY, Tang ZY (2005) Heat-shock protein 27: a potential biomarker
for hepatocellular carcinoma identified by serum proteome analysis.
Proteomics 5: 4581–4588.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates
of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer
127: 2893–2917.
Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q (2010) Role of
carnitine in disease. Nutr Metab 7: 30.
Fye HK, Wright-Drakesmith C, Kramer HB, Camey S, Nogueira da Costa A,
Jeng A, Bah A, Kirk GD, Sharif MI, Ladep NG, Okeke E, Hainaut P,
Taylor-Robinson SD, Kessler BM, Mendy ME (2013) Protein profiling in
hepatocellular carcinoma by label-free quantitative proteomics in two west
african populations. PLoS One 8: e68381.
Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W,
Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G,
Laverny G, Adorini L, Moschetta A, van Mil SW (2011) Farnesoid X
receptor activation inhibits inflammation and preserves the intestinal
barrier in inflammatory bowel disease. Gut 60: 463–472.
Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH
(2012) Urinary acylcarnitines are altered in human kidney cancer. Int J
Cancer 130: 2791–2800.
Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D (2009) Application of
1H NMR-based metabonomics in the study of metabolic profiling of
human hepatocellular carcinoma and liver cirrhosis. Cancer Sci 100:
782–785.
Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P,
Rapaccini GL, Anna Di Nolfo M, Benvegnu` L, Zoli M, Borzio F,
Caturelli E, Chiaramonte M, Trevisani F. Italian Liver Cancer (ITA.LI.CA)
group (2012) Alpha-fetoprotein has no prognostic role in small
hepatocellular carcinoma identified during surveillance in compensated
cirrhosis. Hepatology 56: 1371–1379.
BRITISH JOURNAL OF CANCER
1154 www.bjcancer.com |DOI:10.1038/bjc.2015.38
He QY, Zhu R, Lei T, Ng MY, Luk JM, Sham P, Lau GK, Chiu JF (2008)
Toward the proteomic identification of biomarkers for the prediction of
HBV related hepatocellular carcinoma. J Cell Biochem 103: 740–752.
Heuberger W, Berardi S, Jacky E, Pey P, Kra¨henbu¨hl S (1998) Increased
urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin
Pharmacol 54: 503–508.
Hoi PM, Hiley CR (2006) Vasorelaxant effects of oleamide in rat small
mesenteric artery indicate action at a novel cannabinoid receptor.
Br J Pharmacol 147: 560–568.
Hoppel C (2003) The role of carnitine in normal and altered fatty acid
metabolism. Am J Kidney Dis 41: S4–S12.
Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, Bera R, Sung CM,
Chiu CT (2011) Secreted ERBB3 isoforms are serum markers for early
hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res
10: 4715–4724.
Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, Xu G (2013)
Metabolic characterization of hepatocellular carcinoma using non-targeted
tissue metabolomics. Cancer Res 73: 4992–5002.
Ishihara T, Fukuda I, Morita A, Takinami Y, Okamoto H, Nishimura S,
Numata Y (2011) Development of quantitative plasma N-glycoproteomics
using label-free 2-D LC-MALDI MS and its applicability for biomarker
discovery in hepatocellular carcinoma. J Proteomics 74: 2159–2168.
Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, Liu Y (2010) Serum protein
biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-
MS/MS. J Cancer Res Clin Oncol 136: 1151–1159.
Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M,
Ido A, Nagata K, Hayashi K, Stuver SO, Tsubouchi H (2010)
The complement component C3a fragment is a potential biomarker for
hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 45:
459–467.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X,
Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD,
Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ,
Hazen SL (2013) Intestinal microbiota metabolism of L-carnitine, a
nutrient in red meat, promotes atherosclerosis. Nat Med 19: 576–585.
Kra¨henbu¨hl S (1996) Carnitine metabolism in chronic liver disease. Life Sci
59: 1579–1599.
LaRusso NF, Hoffman NE, Korman MG, Hofmann AF, Cowen AE (1978)
Determinants of fasting and postprandial serum bile acid levels in healthy
man. Am J Dig Dis 23: 385–391.
Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM,
Xiao G, Zhang WM, Lau GK, Yang M, Guan XY (2006) Clusterin plays an
important role in hepatocellular carcinoma metastasis. Oncogene 25:
1242–1250.
Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL,
Lu FJ, Chow LP (2006) Identification of complement C3a as a candidate
biomarker in human chronic hepatitis C and HCV-related hepatocellular
carcinoma using a proteomics approach. Proteomics 6: 2865–2873.
Lee JY, Kim JY, Park GW, Cheon MH, Kwon KH, Ahn YH, Moon MH,
Lee HJ, Paik YK, Yoo JS (2011) Targeted mass spectrometric approach for
biomarker discovery and validation with nonglycosylated tryptic peptides
from N-linked glycoproteins in human plasma. Mol Cell Proteomics 10:
M111 009290.
Linkous AG, Yazlovitskaya EM, Hallahan DE (2010) Cytosolic phospholipase
A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst 102:
1398–1412.
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S (2008)
Sustained complete response and complications rates after radiofrequency
ablation of very early hepatocellular carcinoma in cirrhosis: is resection
still the treatment of choice? Hepatology 47: 82–89.
Llovet JM, Bruix J (2003) Systematic review of randomized trials for
unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 37: 429–442.
Lu Y, Liu J, Lin C, Wang H, Jiang Y, Wang J, Yang P, He F (2010)
Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B
virus related liver fibrosis identified by proteomic analysis of the plasma.
BMC Gastroenterol 10: 115.
Malaguarnera G, Bertino G, Vacante M, Malaguarnera M (2014)
Hepatocellular carcinoma markers in the omics era: the glycomic analysis.
Hepatobiliary Surg Nutr 3: 407–409.
Malaguarnera M (2012) Carnitine derivatives: clinical usefulness. Curr Opin
Gastroenterol 28: 166–176.
Martı´nez-Gonza´lez D, Bonilla-Jaime H, Morales-Otal A, Henriksen SJ,
Vela´zquez-Moctezuma J, Prospe´ro-Garcı´a O (2004) Oleamide and
anandamide effects on food intake and sexual behavior of rats. Neurosci
Lett 364: 1–6.
Masuzaki R, Karp SJ, Omata M (2012) New serum markers of hepatocellular
carcinoma. Semin Oncol 39: 434–439.
Matos JM, Witzmann FA, Cummings OW, Schmidt CM (2009) A pilot study
of proteomic profiles of human hepatocellular carcinoma in the United
States. J Surg Res 155: 237–243.
Mederacke I, Mencin A, Lefkowitch Jay H, Sartor RB, Dapito Dianne H,
Rabadan R, Jang M-K, Pradere J-P, Caviglia Jorge M, Khiabanian H,
Schwabe Robert F, Friedman R, Bower M, Gwak G-Y, Bataller R, Adeyemi
A (2012) Promotion of Hepatocellular Carcinoma by the Intestinal
Microbiota and TLR4.
Michitaka K, Hiraoka A, Kume M, Uehara T, Hidaka S, Ninomiya T,
Hasebe A, Miyamoto Y, Ichiryu M, Tanihira T, Nakahara H, Ochi H,
Tanabe A, Uesugi K, Tokumoto Y, Mashiba T, Abe M, Hiasa Y,
Matsuura B, Onji M (2010) Amino acid imbalance in patients with
chronic liver diseases. Hepatol Res 40: 393–398.
Morgan TR, Mandayam S, Jamal MM (2004) Alcohol and hepatocellular
carcinoma. Gastroenterology 127: S87–S96.
Morita Y, Sakaguchi T, Ikegami K, Goto-Inoue N, Hayasaka T, Hang VT,
Tanaka H, Harada T, Shibasaki Y, Suzuki A, Fukumoto K, Inaba K,
Murakami M, Setou M, Konno H (2013) Lysophosphatidylcholine
acyltransferase 1 altered phospholipid composition and regulated
hepatoma progression. J Hepatol 59: 292–299.
Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, Jeong AS, Cho SY, Kim SA,
Song SY, Kim KS, Cho SW, Kim H, Paik YK (2009) Human plasma
carboxylesterase 1, a novel serologic biomarker candidate for
hepatocellular carcinoma. Proteomics 9: 3989–3999.
Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, Seror O,
Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L (2012a)
Identification of serum proton NMR metabolomic fingerprints associated
with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin
Cancer Res 18: 6714–6722.
Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault JC, Ziol M, Seror O,
Dhonneur G, Trinchet JC, Beaugrand M, Le Moyec L (2012b)
Identification of serum proton NMR metabolomic fingerprints associated
with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin
Cancer Res 18: 6714–6722.
Saito Y, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K,
Nakatsura T (2010) Identification of b2-microgloblin as a candidate for
early diagnosis of imaging-invisible hepatocellular carcinoma in patient
with liver cirrhosis. Oncol Rep 23: 1325–1330.
Neale G, Lewis B, Weaver V, Panveliwalla D (1971) Serum bile acids in liver
disease. Gut 12: 145–152.
Nesvizhskii AI (2007) Protein identification by tandem mass spectrometry
and sequence database searching. Methods Mol Biol 367: 87–119.
Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ
(2009) Urinary creatinine excretion, an indirect measure of muscle mass,
is an independent predictor of cardiovascular disease and mortality in the
general population. Atherosclerosis 207: 534–540.
Paradis V, Degos F, Darge`re D, Pham N, Belghiti J, Degott C, Janeau JL,
Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P (2005)
Identification of a new marker of hepatocellular carcinoma by serum
protein profiling of patients with chronic liver diseases. Hepatology 41:
40–47.
Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T,
Gonzalez FJ, Dufour JF, Idle JR (2011) Aberrant lipid metabolism in
hepatocellular carcinoma revealed by plasma metabolomics and lipid
profiling. Cancer Res 71: 6590–6600.
Ponz De Leon M, Murphy GM, Dowling RH (1978) Physiological factors
influencing serum bile acid levels. Gut 19: 32–39.
Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C,
Degos F, Farges O, Belghiti J (2004) Obesity and diabetes as a risk factor
for hepatocellular carcinoma. Liver Transpl 10: S69–S73.
Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR,
Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R,
Shetty K (2012) Utilization of metabolomics to identify serum biomarkers
for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim
Acta 743: 90–100.
Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P,
Marrero JA, Beretta L (2012) Identification of osteopontin as
BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.38 1155
a novel marker for early hepatocellular carcinoma. Hepatology 55:
483–490.
Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM,
Thillainayagam AV, Thomas HC, Waked I, Khan SA, Taylor-Robinson SD
(2011) Urinary metabolic biomarkers of hepatocellular carcinoma in an
Egyptian population: a validation study. J Proteome Res 10: 1828–1836.
Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A,
Thillainayagam AV, Crossey MM, Khan SA, Thomas HC,
Taylor-Robinson SD (2010) Characterization of urinary biomarkers of
hepatocellular carcinoma using magnetic resonance spectroscopy in a
Nigerian population. J Proteome Res 9: 1096–1103.
Shen Y, Jacobs JM, Camp 2nd DG, Fang R, Moore RJ, Smith RD, Xiao W,
Davis RW, Tompkins RG (2004) Ultra-high-efficiency strong cation
exchange LC/RPLC/MS/MS for high dynamic range characterization of
the human plasma proteome. Anal Chem 76: 1134–1144.
Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT,
Dwek R, Block TM (2003) A strategy for the comparative analysis of
serum proteomes for the discovery of biomarkers for hepatocellular
carcinoma. Proteomics 3: 601–609.
Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM (2010a)
Proteomics of hepatocellular carcinoma: serum vimentin as
a surrogate marker for small tumors (oor¼ 2 cm). J Proteome Res 9:
1923–1930.
Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N, Liu S,
Qian X, Zhao X (2008) Quantitative proteomic signature of liver cancer
cells: tissue transglutaminase 2 could be a novel protein candidate of
human hepatocellular carcinoma. J Proteome Res 7: 3847–3859.
Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L (2010b)
Differential proteomics identification of HSP90 as potential serum
biomarker in hepatocellular carcinoma by two-dimensional
electrophoresis and mass spectrometry. Int J Mol Sci 11: 1423–1433.
Taylor LA, Arends J, Hodina AK, Unger C, Massing U (2007) Plasma
lyso-phosphatidylcholine concentration is decreased in cancer patients
with weight loss and activated inflammatory status. Lipids Health Dis
6: 17.
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A,
Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J,
Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose
homeostasis. Cell Metab 10: 167–177.
Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008)
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov
7: 678–693.
Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L
(2012) Metabonomic profiles discriminate hepatocellular carcinoma from
liver cirrhosis by ultraperformance liquid chromatography-mass
spectrometry. J Proteome Res 11: 1217–1227.
Ward DG, Cheng Y, N’Kontchou G, Thar TT, Barget N, Wei W,
Martin A, Beaugrand M, Johnson PJ (2006) Preclinical and post-treatment
changes in the HCC-associated serum proteome. Br J Cancer 95:
1379–1383.
Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D (2012)
Differentiating hepatocellular carcinoma from hepatitis C using metabolite
profiling. Metabolites 2: 701–716.
Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X (2009) Metabolomic
profiling of human urine in hepatocellular carcinoma patients using gas
chromatography/mass spectrometry. Anal Chim Acta 648: 98–104.
Wu W, Li J, Liu Y, Zhang C, Meng X, Zhou Z (2012) Comparative proteomic
studies of serum from patients with hepatocellular carcinoma. J Invest Surg
25: 37–42.
Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH,
Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H,
Tadesse MG, Ziada DH, Ressom HW (2012) LC-MS based serum
metabolomics for identification of hepatocellular carcinoma biomarkers in
Egyptian cohort. J Proteome Res 11: 5914–5923.
Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, Shen X (2008) A serum
metabolomic investigation on hepatocellular carcinoma patients by
chemical derivatization followed by gas chromatography/mass spectrometry.
Rapid communications in mass spectrometry: RCM 22: 3061–3068.
Yang MH, Tyan YC, Jong SB, Huang YF, Liao PC, Wang MC (2007a)
Identification of human hepatocellular carcinoma-related proteins by
proteomic approaches. Anal Bioanal Chem 388: 637–643.
Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F (2007b)
Metabonomic studies of human hepatocellular carcinoma using high-
resolution magic-angle spinning 1H NMR spectroscopy in conjunction
with multivariate data analysis. J Proteome Res 6: 2605–2614.
Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G
(2009) A metabonomic study of hepatitis B-induced liver cirrhosis and
hepatocellular carcinoma by using RP-LC and HILIC coupled with mass
spectrometry. Mol Biosyst 5: 868–876.
Zhang A, Sun H, Yan G, Han Y, Ye Y, Wang X (2013) Urinary metabolic
profiling identifies a key role for glycocholic acid in human liver cancer by
ultra-performance liquid-chromatography coupled with high-definition
mass spectrometry. Clin Chim Acta 418: 86–90.
Zhao Y, Jia W, Sun W, Jin W, Guo L, Wei J, Ying W, Zhang Y, Xie Y, Jiang Y,
He F, Qian X (2010) Combination of improved (18)O incorporation and
multiple reaction monitoring: a universal strategy for absolute quantitative
verification of serum candidate biomarkers of liver cancer. J Proteome Res
9: 3319–3327.
Zhou L, Ding L, Yin P, Lu X, Wang X, Niu J, Gao P, Xu G (2012a)
Serum metabolic profiling study of hepatocellular carcinoma infected with
hepatitis B or hepatitis C virus by using liquid chromatography-mass
spectrometry. J Proteome Res 11: 5433–5442.
Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, Lu X, Zhang Y, Lin X, Xu G
(2012b) Serum metabolomics reveals the deregulation of fatty acids
metabolism in hepatocellular carcinoma and chronic liver diseases.
Anal Bioanal Chem 403: 203–213.
BRITISH JOURNAL OF CANCER
1156 www.bjcancer.com |DOI:10.1038/bjc.2015.38
